SUNSHINE PHARMA (06887): Ologlitazin Capsules Successfully Included in the 2026 Edition of the National Reimbursement Drug List

SUNSHINE PHARMA (06887) announced that recently, the Group's independently developed sodium-glucose cotransporter 2 inhibitor (SGLT-2 inhibitor), a Class 1 innovative drug Ologlitazin Capsules (trade name: Dongze'an), has been successfully included in the latest edition of the "National Drug Catalog for Basic Medical Insurance, Work-Related Injury Insurance and Maternity Insurance (2026)" published by China's National Healthcare Security Administration. The 2026 edition of the national medical insurance drug catalog will be officially implemented starting January 1, 2027. The product obtained marketing approval from China's National Medical Products Administration in January 2026 and can be used as monotherapy or in combination with metformin to improve glycemic control in adult patients with type 2 diabetes mellitus (T2DM). The product is an SGLT2 inhibitor independently developed by the Group with independent intellectual property rights. It can promote urinary glucose excretion by potently inhibiting renal SGLT2, and moderately inhibit intestinal SGLT1 to reduce glucose or galactose absorption, effectively reducing dramatic postprandial blood glucose fluctuations and achieving "full-course, dual-channel" synergistic control of both fasting and postprandial blood glucose. The product's registration approval was based on two multicenter, randomized, double-blind, controlled Phase III clinical studies. The two Phase III clinical studies showed that Ologlitazin as monotherapy or in combination with metformin for 24 weeks significantly reduced glycated hemoglobin (HbA1c), comprehensively lowered fasting blood glucose and postprandial blood glucose, and delivered multiple benefits including improvements in blood pressure and body weight, with efficacy sustained through 52 weeks. It demonstrated outstanding effects in improving energy metabolism, aligning with the current comprehensive management trend of "blood glucosebody weightblood pressure" in diabetes. During clinical trials, the product was generally well tolerated, with no significant difference in the incidence of adverse reactions compared with the placebo group.